FV-100

FV-100
Names
IUPAC name
3-(2-Deoxy-β-D-erythro-pentofuranosyl)-6-(4-pentylphenyl)furo[2,3-d]pyrimidin-2(3H)-one
Systematic IUPAC name
3-[(2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(4-pentylphenyl)furo[2,3-d]pyrimidin-2(3H)-one
Other names
Cf1743
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
  • InChI=1S/C22H26N2O5/c1-2-3-4-5-14-6-8-15(9-7-14)18-10-16-12-24(22(27)23-21(16)29-18)20-11-17(26)19(13-25)28-20/h6-10,12,17,19-20,25-26H,2-5,11,13H2,1H3/t17-,19+,20+/m0/s1
    Key: MFGSDSRTGUVZQG-DFQSSKMNSA-N
  • CCCCCC1=CC=C(C=C1)C2=CC3=CN(C(=O)N=C3O2)[C@H]4C[C@@H]([C@H](O4)CO)O
Properties
C22H26N2O5
Molar mass 398.459 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
X markN verify (what is checkYX markN ?)

FV-100, also known as Cf1743, is an orally available nucleoside analogue drug with antiviral activity. It may be effective against shingles.

It was discovered in 1999 in the laboratories of Prof Chris McGuigan, Welsh School of Pharmacy and Prof. Jan Balzarini, Rega Institute, Leuven, Belgium.

Clinical trials

FV-100 was tested against valaciclovir in a phase II trial in patients with herpes zoster. The trial was sponsored by Bristol-Myers Squibb. The drug is currently being developed by ContraVir Pharmaceuticals, Inc., Edison, New Jersey. It has reached Phase III clinical trials.

References

  1. ↑ Inhibitex Completes Phase I Clinical Trials For FV-100 And Selects Lead HCV Compounds For Advanced Preclinical Studies, 2009, archived from the original on 2009-02-15, retrieved 2010-04-08
  2. ↑ McGuigan, Christopher; Balzarini, Jan (2009). "FV100 as a new approach for the possible treatment of varicella-zoster virus infection". Journal of Antimicrobial Chemotherapy. 64 (4): 671–673. doi:10.1093/jac/dkp294. PMID 19679595.
  3. ↑ Tyring SK, Lee P, Hill GT Jr, Silverfield JC, Moore AY, Matkovits T, Sullivan-Bolyai J (Jul 2017). "FV-100 versus valacyclovir for the prevention of post-herpetic neuralgia and the treatment of acute herpes zoster-associated pain: A randomized-controlled trial". J Med Virol. 89 (7): 1255–1264. doi:10.1002/jmv.24750. PMC 6139434. PMID 27943311.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  4. ↑ Cardiff School of Pharmacy; Pharmaceutical Sciences, Step forward for shingles drug - FV100. Shows structure of FV100.
  5. ↑ A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster, 23 September 2015
  6. ↑ "ContraVir Pharmaceuticals: FDA Meeting About Antiviral Drug Trial.", Drug Discovery & Development, January 2015
  7. ↑ De Clercq E, Li G (Jul 2016). "Approved Antiviral Drugs over the Past 50 Years". Clin Microbiol Rev. 29 (3): 695–747. doi:10.1128/CMR.00102-15. PMC 4978613. PMID 27281742.